… features; and (3) slow, stop, or reverse disease progression. This article will consider the
prospects of developing therapies that meet these unmet needs. Therapeutic Pipeline—2013 …

l-Dopa has long been the mainstay of therapy for Parkinson's disease but its long-term
shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and …

… of Parkinson's disease (PD), a sickness inflicting multiple physiological and behavioral
abnormalities. Chemical replacement therapy … of the behavioral symptoms of the disease, but this …

… for the pathobiology of Parkinson's disease. Antioxid Redox … of Parkinson's disease. Prog
Neurobiol 2009; 89: 277-87. … Alzheimer's and de novo Parkinson's disease patients. Neurosci …

Parkinson’s disease (PD) is a neurodegenerative disorder pathologically distinguished by
degeneration of dopaminergic neurons in the substantia nigra pars compacta. Muscle rigidity, …

PD is an attractive target for central nervous system (CNS) gene therapy for several reasons.
First, the pathology in early PD is, to a first approximation, limited to dopaminergic neurons …

Parkinson’s disease (PD) is caused by the degeneration of dopaminergic neurons of substantia
nigra projecting to striatum. The cause of idiopathic PD is obscure, and most cases are …

… disease now offers novel prospects for therapy based on targeted neuroprotection of vulnerable
neurons and effective strategies for their replacement. Parkinson's disease … Parkinson in …

… in medical history for James Parkinson's by addition of more symptoms to … Parkinson's
disease (PD) for those symptoms [4]. Being the second most familiar ND after Alzheimer's disease …

Cell replacement therapy in Parkinson's disease (PD) has so far been based on the use of
primary dopaminergic (DA) neuroblasts obtained from the brain of aborted human fetuses. …